S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Free Stock Analysis Report: Invest Smarter With Powerful Data (Ad)pixel
Bank failures and rescue test Yellen's decades of experience
Germany, EU reach agreement in combustion engine row
Modern Day Options Trading For Beginners! (Ad)pixel
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Free Stock Analysis Report: Invest Smarter With Powerful Data (Ad)pixel
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Free Stock Analysis Report: Invest Smarter With Powerful Data (Ad)pixel
Bank failures and rescue test Yellen's decades of experience
Germany, EU reach agreement in combustion engine row
Modern Day Options Trading For Beginners! (Ad)pixel
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Free Stock Analysis Report: Invest Smarter With Powerful Data (Ad)pixel
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Free Stock Analysis Report: Invest Smarter With Powerful Data (Ad)pixel
Bank failures and rescue test Yellen's decades of experience
Germany, EU reach agreement in combustion engine row
Modern Day Options Trading For Beginners! (Ad)pixel
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Free Stock Analysis Report: Invest Smarter With Powerful Data (Ad)pixel
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Free Stock Analysis Report: Invest Smarter With Powerful Data (Ad)pixel
Bank failures and rescue test Yellen's decades of experience
Germany, EU reach agreement in combustion engine row
Modern Day Options Trading For Beginners! (Ad)pixel
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Free Stock Analysis Report: Invest Smarter With Powerful Data (Ad)pixel
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
NASDAQ:ATRA

Atara Biotherapeutics - ATRA Stock Forecast, Price & News

$2.87
+0.01 (+0.35%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.76
$2.90
50-Day Range
$2.83
$5.46
52-Week Range
$2.66
$10.01
Volume
1.70 million shs
Average Volume
1.48 million shs
Market Capitalization
$275.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.86

Atara Biotherapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.14 Rating Score
Upside/​Downside
570.7% Upside
$19.25 Price Target
Short Interest
Bearish
14.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
0.71mentions of Atara Biotherapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$129,165 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.17) to ($1.62) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

790th out of 1,005 stocks

Biological Products, Except Diagnostic Industry

136th out of 168 stocks


ATRA stock logo

About Atara Biotherapeutics (NASDAQ:ATRA) Stock

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Receive ATRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATRA Stock News Headlines

"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
See More Headlines
Receive ATRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATRA Company Calendar

Last Earnings
2/08/2023
Today
3/25/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATRA
Fax
N/A
Employees
578
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.25
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+417.7%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
7 Analysts

Profitability

Net Income
$-228,300,000.00
Net Margins
-359.12%
Pretax Margin
-359.10%

Debt

Sales & Book Value

Annual Sales
$63.57 million
Book Value
$1.33 per share

Miscellaneous

Free Float
92,090,000
Market Cap
$275.32 million
Optionable
Optionable
Beta
0.99

Key Executives

  • Pascal TouchonPascal Touchon
    President, Chief Executive Officer & Director
  • Utpal KoppikarUtpal Koppikar
    Chief Financial Officer & Senior Vice President
  • Manher AJ Joshi
    Chief Medical Officer
  • Jakob DupontJakob Dupont
    Global Head-Research & Development
  • Anhco Nguyen
    Chief Scientific Officer













ATRA Stock - Frequently Asked Questions

Should I buy or sell Atara Biotherapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last year. There are currently 2 sell ratings, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ATRA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATRA, but not buy additional shares or sell existing shares.
View ATRA analyst ratings
or view top-rated stocks.

What is Atara Biotherapeutics' stock price forecast for 2023?

7 equities research analysts have issued 1 year target prices for Atara Biotherapeutics' stock. Their ATRA share price forecasts range from $3.00 to $50.00. On average, they anticipate the company's share price to reach $19.25 in the next year. This suggests a possible upside of 570.7% from the stock's current price.
View analysts price targets for ATRA
or view top-rated stocks among Wall Street analysts.

How have ATRA shares performed in 2023?

Atara Biotherapeutics' stock was trading at $3.28 on January 1st, 2023. Since then, ATRA shares have decreased by 12.5% and is now trading at $2.87.
View the best growth stocks for 2023 here
.

When is Atara Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our ATRA earnings forecast
.

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) released its quarterly earnings results on Wednesday, February, 8th. The biotechnology company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.61) by $0.11. The biotechnology company had revenue of $0.22 million for the quarter, compared to analysts' expectations of $60 million. Atara Biotherapeutics had a negative net margin of 359.12% and a negative trailing twelve-month return on equity of 140.05%.

What ETFs hold Atara Biotherapeutics' stock?
What is Pascal Touchon's approval rating as Atara Biotherapeutics' CEO?

38 employees have rated Atara Biotherapeutics Chief Executive Officer Pascal Touchon on Glassdoor.com. Pascal Touchon has an approval rating of 60% among the company's employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 88.0% of employees surveyed would recommend working at Atara Biotherapeutics to a friend.

What other stocks do shareholders of Atara Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), OPKO Health (OPK), Gilead Sciences (GILD), Micron Technology (MU) and Pfizer (PFE).

What is Atara Biotherapeutics' stock symbol?

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

Who are Atara Biotherapeutics' major shareholders?

Atara Biotherapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (7.82%), Maverick Capital Ltd. (6.56%), Morgan Stanley (2.80%), Geode Capital Management LLC (1.92%), Citigroup Inc. (1.08%) and Dimensional Fund Advisors LP (0.94%). Insiders that own company stock include Amar Murugan, Jakob Dupont, Joe Newell, Kristin Yarema, Matthew K Fust, Pascal Touchon, Thomas Peterffy and Utpal Koppikar.
View institutional ownership trends
.

How do I buy shares of Atara Biotherapeutics?

Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atara Biotherapeutics' stock price today?

One share of ATRA stock can currently be purchased for approximately $2.87.

How much money does Atara Biotherapeutics make?

Atara Biotherapeutics (NASDAQ:ATRA) has a market capitalization of $275.32 million and generates $63.57 million in revenue each year. The biotechnology company earns $-228,300,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis.

How many employees does Atara Biotherapeutics have?

The company employs 578 workers across the globe.

How can I contact Atara Biotherapeutics?

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.atarabio.com. The biotechnology company can be reached via phone at (805) 623-4211 or via email at ehyllengren@atarabio.com.

This page (NASDAQ:ATRA) was last updated on 3/25/2023 by MarketBeat.com Staff